Background Advanced non-small cell lung cancer (NSCLC) remains an incurable disease. Immunotherapies that activate patients' T cells against resident tumor cells are being developed; however, these approaches may not be eVective in NSCLC patients due to tumor-induced immune suppression. A major cause of immune suppression is myeloid-derived suppressor cells (MDSC). Because of the strategic role of CD4 + T lymphocytes in the activation of cytotoxic CD8 + T cells and immune memory, we are developing cell-based vaccines that activate tumor-speciWc CD4 + T cells in the presence of MDSC. The vaccines are NSCLC cell lines transfected with costimulatory (CD80) plus major histocompatibility complex class II (MHC II) genes that are syngeneic to the recipient. The absence of invariant chain promotes the presentation of endogenously synthesized tumor antigens, and the activation of MHC II-restricted, tumor-antigen-speciWc CD4 + T cells. Methods Potential vaccine eYcacy was tested in vitro by priming and boosting peripheral blood mononuclear cells from ten NSCLC patients who had varying levels of MDSC. CD4 + T cell activation was quantiWed by measuring Type 1 and Type 2 cytokine release. Results The vaccines activated CD4 + T cells from all ten patients, despite the presence of CD33 + CD11b + MDSC. Activated CD4 + T cells were speciWc for NSCLC and did not cross-react with tumor cells derived from non-lung tissue or normal lung Wbroblasts. Conclusions The NSCLC vaccines activate tumor-speciWc CD4 + T cells in the presence of potent immune suppression, and may be useful for the treatment of patients with NSCLC.
Introduction
Lung cancer is a major cause of morbidity throughout the world [16] , with more than 1 million new cases diagnosed annually [28] . Despite the existing treatments of surgery, radiotherapy, chemotherapy, and multimodal therapies, the long term survival of patients remains low [24, 28, 32] . Because of the high mortality rate, alternative strategies for the treatment of lung cancer are being developed, including novel agents aimed at activating a patient's immune response to lung cancer cells. Some of these immuneenhancing approaches have shown preclinical eYcacy, and have modest eVects in a small subset of patients in clinical trials; however, none have been curative and the majority of patients do not respond [24, 28, 32] . Many of these treatments are "active" immunotherapies that require patients to be immunocompetent. However, individuals with cancer are frequently immunosuppressed, and this immune suppression may block the ability to respond to the therapy [8, 11, 19] .
Various populations of cells and soluble factors produced by cells have been identiWed in cancer patients and shown to mediate immune suppression. These include, myeloidderived suppressor cells (MDSC) [34, 46] , T regulatory cells (T regs) [37] , and soluble factors such as TGF [22] . MDSC are a heterogeneous population of cells of myeloid origin that are present in many cancer patients, including patients with non-small cell lung cancer (NSCLC) [1] . They suppress immunity through multiple pathways, including the inhibition of T cell activation [1, 6, 21, 39] , the blocking of NK cell cytotoxicity [42] , the induction of T regulatory cells [14] , the production of IL-10 [38] , and by decreasing macrophage production of IL-12 [38] .
We are focusing on developing immunotherapies for the treatment of advanced stages of lung cancer. Because CD4 + T cells are critical for activating CD8 + T cells and for the induction of immunological memory [15, 35] , we have designed cell-based vaccines that activate tumor-speciWc CD4 + T cells. Since >70% of lung cancer patients have NSCLC [24] , we are focusing our eVorts on this group of patients. To activate CD4 + T cells, we have genetically engineered lung cancer cell lines to express major histocompatibility complex class II (MHC II) molecules and a co-stimulatory molecule (CD80) in the absence of invariant chain (Ii), an MHC II chaperone protein that is present in professional antigen presenting cells (APC), such as dendritic cells (DC). Ii promotes the presentation of exogenous antigen, and its absence facilitates the presentation of endogenously synthesized antigen [23] . Therefore, tumor cells that express syngeneic MHC II and costimulatory molecules and do not express Ii, should activate MHC II syngeneic CD4 + T cells to endogenously synthesized tumor antigens. We have called these genetically modiWed tumor cells "MHC II vaccines," and previous studies using uveal melanoma and breast cancer cells demonstrate that they activate a novel repertoire of tumor-speciWc CD4 + T cells [45] from healthy donors [9] and from uveal melanoma patients [5] . Since the role of the activated CD4 + T cells is to provide help to CD8 + T cells and to facilitate the development of immune memory, the activated CD4 + T cells do not need to directly react with patients' tumor cells. Therefore, MHC II and/or CD80 on the patients' tumor cells is not required.
Since MDSC have been found in patients with NSCLC [1] , we are determining their eVects on NSCLC patients' responsiveness to MHC II lung cancer vaccines. We show that despite varying levels of MDSC in NSCLC patients, CD4 + T cells from these individuals are activated in vitro by the MHC II lung cancer vaccines, suggesting that NSCLC patients may be candidates for active immunotherapy with the MHC II vaccines.
Materials and methods

Cells
SUM159PT and MCF10CA1 (hereafter called MCF10) mammary carcinomas and OMM2.3 uveal melanoma cells were maintained as described [5, 9, 44] . The human NSCLC cell lines H358 (bronchioloalveolar adenocarcinoma) and HTB-177 (large cell carcinoma; hereafter called H177), and normal lung Wbroblasts were obtained from the American type culture collection. Tumor lines were cultured in tumor medium (RPMI supplemented with 10% heat inactivated fetal calf serum, 1.5 g/l sodium bicarbonate, 10 mM HEPES, 1.0 mM sodium pyruvate, 1% penicillin/streptomycin (Biosource, Rockville, MD, USA), 2 mM glutamax (BRL/Life Sciences, Grand Island, NY, USA) and 1% gentamycin). Fibroblasts were cultured in Wbroblast medium (DMEM supplemented with 10% heat inactivated fetal calf serum, 1.5 g/l sodium bicarbonate, 10 mM HEPES, 1.0 mM sodium pyruvate, 1% penicillin/streptomycin, 2 mM glutamax, and 0.1 mM non-essential amino acids (BRL/Life Sciences). MCF10 cells transduced with DR7, CD80, or Ii (MCF10/ DR7/CD80, MCF10/DR7/CD80/Ii), Jurkat, and Sweig cells were maintained as previously described [45] . HLA genotypes of the NSCLC cell lines are shown in Table 1 . Procedures with human materials were approved by the Institutional Review Boards of the participating institutions.
IFN treatment
A total of 2 £ 10 5 cells were incubated at 37°C, 5% CO 2 for 48 h in six well plates in 3 ml of their culture medium containing 200 U/ml recombinant human IFN (Pierce Biotechnology, Rockford, IL, USA).
Antibodies and immunoXuorescence
Monoclonal antibodies W6/32 (pan HLA-A, B, C), L243 (pan HLA-DR), and PIN1.1 (Ii) were prepared as described [9] . CD80-PE, CD19-FITC, mouse FITC (IgG2a) and PE isotype (IgG2a) controls, and streptavidin-PerCP were from BD PharMingen (San Jose, CA, USA). CD4-FITC, CD8-FITC, and goat-anti-mouse magnetic beads were from Miltenyi Biotech (Auburn, CA, USA). CD33-FITC and CD11b-PE were from SeroTec (Raleigh, NC, USA). CD3-PE, CD56-FITC, CD68-PE, CD11c-PE, DEC205-FITC, and CD15-biotin were from eBioscience (San Diego, CA, USA). Goat-anti-mouse IgG-FITC was from ICN (Costa Mesa, CA, USA). Live tumor cells or peripheral blood mononuclear cells (PBMC) were stained for cell surface markers (CD4, CD8, CD56, CD3, CD11b, and CD80), and Wxed and permeabilized cells were stained for internal markers (FoxP3 or Ii). ImmunoXuorescence and Xow cytometry were performed as described [9] .
Western blots
Western blots for Ii were performed as described [5, 44] using PIN1.1 mAb followed by sheep-anti-mouse-HRP (Amersham) at a 1:5,000 dilution.
Patient and healthy donor PBMC, HLA typing, and HLA nomenclature Blood samples from healthy donors BC123104, BC011405, BC120204, BC100504, and BC100706 and lung cancer patients 1, 3, 4, 5, 6, 7, 8, 9, 10, and 11, were obtained by venipunture and the resulting cells puriWed by Ficoll gradient and stored in liquid nitrogen as described [9] . PBMC that were >80% viable after thawing were used. PBMC and lung cancer cell lines were HLA-typed and analyzed using MicroSSP™ HLA Class I and II ABDR DNA typing trays and analysis software (One Lambda, Inc., Canoga Park, CA, USA) according to the manufacturer's instructions. Stage of disease, treatments of NSCLC patients, and HLA genotypes of patients and healthy donors used in the T cell activation studies are shown in Table 1 . HLA genotypes are referred to by their short hand form (e.g. HLA-DRB1*0701 is HLA-DR7).
CD4, CD8 and CD33 cell depletions
Peripheral blood mononuclear cells were depleted for CD4 + , CD8 + , or CD33 + cells using magnetic beads, LD or LS columns, and QuadroMACS separation system according to the manufacturer's instructions (Miltenyi Biotech) as described [9] . Depleted populations were conWrmed by Xow cytometry and <5% of depleted populations were present in the Wnal populations.
PuriWcation of peripheral blood CD11b
+ CD33 + MDSC CD11b + CD33 + cells were positively puriWed from patients' PMBC using CD33-magnetic beads according to the manufacturer's instructions (Miltenyi Biotech). BrieXy, PBMC were washed twice with degassed cold MACS buVer (0.5% BSA in PBS with 2 mM EDTA) and 1¡2 £ 10 7 washed cells were incubated with anti-human CD33 microbeads (1:5 dilution) for 15 min at 4°C. The resulting cells were 
DNA constructs and transfection
Human lung cancer lines were stably transfected with pLHCX/CD80, pLNCX2/DR7, pLNCX2/DR4, and/or pLNXC2/DR1 [9] constructs by Nucleofector™ technology according to the manufacturer's instructions (Amaxa Biosystems). BrieXy, 1-2 £ 10 6 tumor cells were resuspended in 100 l of Nucleofector solution V with 8-10 l of DNA (1.5-2 g), transferred to a cuvette, and immediately subjected to nucleofection using program T-20. Nucleofected cells were then removed from the cuvette by addition of 500 l RPMI medium and cultured in 3 ml of complete tumor cell culture medium in a six well plate. After 48 h of culture, transfected cells were grown for 3-4 days in complete culture medium supplemented with hygromycin (CD80 transfectants; Calbiochem, San Diego, CA, USA) or G418 (MHC II transfectants; Sigma, St. Louis, MO, USA). Stable transfectants were obtained by multiple rounds of drug treatment followed by magnetic bead sorting using L243 and CD80 primary mAbs and goat-anti-mouse beads as described [9] . Stable transfectants were grown in the same culture medium as their parental cells. CD80 and MHC II levels were assessed by Xow cytometry periodically over the course of a year and remained constant.
T cell activation by anti-CD3 and anti-CD28
Round bottom 96-well plates (BD Falcon™, Franklin Lakes, NJ, USA) were coated overnight at 4°C with 100 l of 1 g/ml anti-CD3 antibody (BD Pharmingen) diluted 1:1 with PBS. Unbound anti-CD3 antibody was removed by washing with excess PBS and 1 £ 10 5 PBMC in 200 l of T cell medium (Iscove's modiWed Dulbecco's medium, 5% human AB serum (Gemini Bio-Products, Woodland, CA, USA), 1% penicillin, 1% streptomycin, 2 mM glutamax, 1.0 mM sodium pyruvate, 5 £ 10 -5 M -mercaptoethanol, 10 mM HEPES, 1% gentamycin) containing soluble anti-CD28 antibody at 2 g/ml were added. Cells were cultured at 37°C for 72 h, and each well then pulsed with 1 Ci Cytokine measurements IL-2, IL-5, IL-10, IL-12, and some IL-4 levels were measured at the University of Maryland, Baltimore cytokine analysis facility by multiplex analysis, using a Luminex 100 system and Xuorescent microbeads [http://www.cytokines. com]. IFN-and some IL-4 levels were measured by ELISA as previously described [44] .
Statistical analysis
Mean, SD, and statistical signiWcance as measured by Student's t test were calculated using Excel (Windows XP professional). Figure 1a shows representative Xow cytometry proWles of cells from three patients (patients 3, 6, and 11) and healthy donor BC123104. These patients have varying levels of CD11b + CD33 + cells, most of which also express CD15, consistent with the interpretation that the CD11b + CD33 + population in the peripheral blood of NSCLC patients is predominantly MDSC. These cells, as visualized by H&E staining are a heterogenous mixture of cells with myeloid characteristics (Fig. 1b) . Table 2 To determine if the CD11b + CD33 + population is suppressive, PBMC from >>NSCLC patients 6, 7, and 11 were activated in vitro with anti-CD3 and anti-CD28 antibodies in the presence or absence of the CD11b + CD33 + cells (Fig. 1c) (Fig. 3a) . Vaccine cells and responding PBMC were syngeneic for MHC II alleles to optimize an MHC class II-restricted response. Previous studies established that allogeneic MHC class I diVerences between vaccine cells and responding T cells do not activate IFNproducing CD4 + T cells [5] , so the vaccine cells and PBMC were not matched for MHC I alleles. T cell activation was assessed by quantifying IFN in the culture supernatants (Fig. 3b) . Maximal PBMC activation was achieved by priming and boosting with H358/DR7/CD80 vaccine cells, whereas, priming with H358/DR7/CD80 and boosting with H358 cells that lack either DR7 or CD80 is signiWcantly less eVective. Priming with unmodiWed parental cells (H358) followed by boosting with H358, H358/DR7, H358/CD80, or H358/DR7/CD80 cells did not activate T cells. Similar results were obtained using PBMC from another HLA-DR7 healthy donor (BC011405), as well as from an HLA-DR4 donor primed and boosted with H358/ DR4/CD80 cells (data not shown). Therefore, genetically modiWed bronchioloalveolar NSCLC cells eYciently activate PBMC from healthy donors, provided they co-express HLA-DR and CD80 molecules.
Results
Lung
To identify the population of T cells that is activated by the MHC II vaccine cells, PBMC from healthy donor BC123104 were depleted for CD8 + or CD4 + T cells prior to priming and boosting with H358/DR7/CD80 vaccine cells (Fig. 3c) . Depletion of CD4 + T cells abolished IFN release, while depletion of CD8 + T cells had no eVect. Therefore, the vaccine speciWcally activates MHC IIrestricted, CD4 + T cells. T cells have been termed "type 1" or "type 2" depending on the spectrum of cytokines they produce, and type 1 responses are considered beneWcial for anti-tumor immunity [17] . To determine which type of response is induced by the vaccines, PBMC from healthy donor BC123104 were primed with irradiated H358/DR7/CD80 cells and boosted with parental H358, H358/DR7, or H358/DR7/ CD80 cells, and the resulting supernatants analyzed for cytokines by multiplex luminex assay (Fig. 3d) . The high level of IFN production is indicative of a type 1 response, with minimal type 2 cytokine (IL-4, IL-5, and IL-10) production. Therefore, the vaccine activates a type 1 CD4 + T cell response.
The MHC II vaccines are designed to activate CD4 + T cells that are speciWc for NSCLC so they can be used as therapeutic agents in NSCLC patients. Since the vaccination strategy uses established cell lines such as H358, it is necessary for these cell lines to activate CD4 + T cells that cross-react with the patient's tumor cells. Cross-reactivity could occur if established cell lines such as H358 share antigens with other NSCLC cells. To test this hypothesis PBMC from HLA-DR7 healthy donor BC123104 were primed with H358/DR7/CD80 vaccine cells and boosted with the priming vaccine, or with DR7 + CD80 + vaccine cells prepared from a large cell carcinoma of the lung (H177/ DR7/CD80), a breast adenocarcinoma (MCF10/DR7/ CD80), or a uveal melanoma (OMM2.3/DR7/CD80) (Fig. 3e, f) . PBMC primed with the H358/DR7/CD80 vaccine were eYciently boosted by the priming vaccine cells as well as by vaccine cells prepared from the large cell carcinoma of the lung (H177/DR7/CD80). In contrast, boosting with either the breast carcinoma or uveal melanoma (Fig. 4a-c) . Although there were quantitative diVerences in the responses of the patients, overall the MHC II vaccines induced robust CD4 + T cell IFN responses from both the NSCLC patients and healthy donor. Similar responses were seen for PBMC from the other six NSCLC patients (data not shown) which contained CD11b + CD33
+ cells ranging from 14-37%. Therefore, CD11b + CD33 + suppressor cells in lung cancer patients do not prevent the vaccines from activating tumor-speciWc, IFN -secreting CD4 + T cells. CD11b + CD33 + cells are maintained through the priming phase of the cultures; however, they decrease in number with time (Srivastava and Ostrand-Rosenberg, unpublished results). Therefore, the lack of suppression in Fig. 4a- + CD33 + cells), were co-cultured with H358/DR7/ CD80 vaccine cells and proliferation of the primed T cells was measured (Fig. 4d) . PBMC from the healthy donor and from the CD11b + CD33
+ -depleted patient's PBMC proliferated well in response to priming with the vaccine cells, whereas, there was minimal proliferation by the non-depleted patient's PBMC. Therefore, CD11b + CD33
+ cells inhibit the vaccine-induced proliferation of T cells during priming, and removal of the CD11b + CD33 + cells restores T cell proliferation.
To determine if the deWcit in proliferation during priming reduces the Wnal yield of T cells, the number of CD4 + T cells in the PBMC of healthy donor BC123104 and patient 6 was quantiWed on day nine after expansion with IL-15 
and immediately before boosting. Although patient 6 initially had fewer CD4 + T cells than the healthy donor, the yield of activated CD4 + T cells from patient 6 was similar to the yield from the healthy donor (55% vs. 44% for patient 6 and the healthy donor, respectively). Therefore, although CD11b + CD33 + MDSC inhibit the initial proliferation of CD4 + T cells, the MHC II lung cancer vaccines prime and boost IFN -secreting, tumor-speciWc CD4 + T cells and overcome the initial proliferation deWcit.
MHC II NSCLC vaccines activate T cells that react with malignant lung cancer cells, and not with normal lung Wbroblasts
Since the MHC II NSCLC vaccines are made from lung cancer cells, they contain antigens that are potentially expressed by non-malignant cells. To determine if the vaccines activate CD4 + T cells against non-malignant cells, HLA-DR7 + PBMC from patient 10 (28% CD11b + CD33 + cells) and healthy donor BC123104 were primed with H358/DR7/CD80 vaccine cells and boosted with the priming vaccine cells, parental H358 cells, or non-malignant lung Wbroblasts (Fig. 4e, f) . Strong responses were produced against the vaccine; however, virtually no response was elicited by the Wbroblasts. Similar results have been observed with PBMC from patient 5 and healthy donor BC011405 (data not shown). Therefore, the MHC II NSCLC vaccines activate T cells that are reactive with malignant NSCLC cells, and do not activate T cells reactive with non-malignant cells from the lung.
Discussion
Despite advances in chemotherapy and radiation therapy, advanced lung cancer remains an incurable disease. The speciWcity and potential potency of the immune system for recognizing and destroying malignant cells has prompted investigators to explore novel strategies for activating patients' T lymphocytes against cancer cells. Although several of these strategies have shown promise in experimental animals with small tumors, they have been disappointing in clinical trials (reviewed in [24, 28, 32] ). One reason for these results may be tumor-induced immune suppression, a condition that accompanies tumor progression and exists in most patients with advanced cancer [11] . A major cause of immune suppression in cancer patients is MDSC, a cell population that blocks adaptive and innate immunity [1, 34] . Here, we report that despite the presence of MDSC in the peripheral blood of NSCLC patients, our novel MHC II lung cancer vaccines activate tumor-speciWc CD4 + T cells from NSCLC patients.
Although MDSC were Wrst observed over 23 years ago when they were called "natural suppressor cells" [41] , they have only recently been acknowledged as a complicating factor for immunotherapy [1, 34] . MDSC interfere with adaptive immunity by inhibiting the activation of CD4 + and CD8 + T cells [6, 20, 39] . In addition, they block innate immunity by inactivating natural killer cells [42] and they skew immunity towards a tumor-promoting type 2 pheno- type through their production of IL-10 and their down-regulation of IL-12 production by macrophages [38] . Since the accumulation and retention of MDSC is regulated by tumor-secreted factors as well as by factors produced by the tumor micro-environment [20] , patients with advanced cancer can have high levels of MDSC. As a result, immunotherapies which require an active immune response in the recipient, must overcome signiWcant immune suppression.
A variety of experimental immunotherapies have been tested in advanced stage (IIIB and IV) NSCLC patients. These include peptide vaccines prepared from single [3] or multiple [24] peptides derived from NSCLC cells, as well as DC pulsed with peptides derived from NSCLC cells [13] . The glycoprotein MUC-1 [7] and epidermal growth factor [33] , both of which are found on many tumor cells including NSCLC cells, have also been tested as therapeutic vaccines. These vaccines did not cause signiWcant sideeVects; however, their therapeutic eYcacy remains to be determined.
Two cell-based vaccines have also been tested. GM-CSF-transduced autologous NSCLC cells induced a 10% response rate in advanced stage patients [27] . However, this treatment may not be practical for large numbers of patients because it requires the transduction of individual patients' tumor cells [26] . More promising is a vaccine generated by transfecting allogeneic NSCLC cells with the costimulatory molecule CD80 [30, 31] . Nineteen patients with advanced disease were treated with this vaccine. One patient had a partial response and Wve had stable disease at the end of the initial 18 month observation period. A recent review reports that four of these patients remain alive with an overall survival time of 36-63 months [32] , compared with the 8-12 month survival time for late stage NSCLC patients who fail initial chemotherapy [36] . The MHC II vaccines described in the current report are similar to this CD80 vaccine in that both are MHC I allogeneic NSCLC cells and are transfected with CD80. The MHC II vaccines have the additional beneWt of activating tumor-speciWc CD4 + T cells because they express syngeneic HLA-DR alleles. This added activity may not only improve the immediate therapeutic eVect of the vaccine, but may also provide long-term protection against tumor progression and/or recurrence.
Our Wnding that the MHC II vaccines activate T cells in the presence of MDSC suggests that this cell-based vaccine may be eYcacious in late stage NSCLC patients who are immune suppressed. Further support is provided by studies Prime: H358/DR4/CD80 MDSC added to boost with a vaccine consisting of NSCLC cells transduced with an anti-sense construct for TGF [25] . TGF is an immune suppressive cytokine that is present in many cancer patients, and the prognosis for NSCLC patients with high levels of plasma TGF is poor [19] . Treatment of advanced stage NSCLC patients with an anti-sense TGF vaccine produced a 15% partial response rate, suggesting that inactivation of TGF may facilitate the development of therapeutic tumor immunity. Since the MHC II vaccines activate T cells despite the presence of MDSC and some MDSC suppress via the production of TGF [43] , the MHC II vaccines may by-pass TGF -induced suppression and therefore induce immunity in late stage NSCLC patients.
To maximize potential recipients and maintain feasibility, we are preparing MHC II vaccines from established, allogeneic tumor cells [5] . This approach will only be eVective if diVerent lung tumor cells share common antigens. Our Wndings that T cells primed with an MHC II bronchioloalveolar adenocarcinoma vaccine cross-react with a large cell lung carcinoma, combined with the Wndings of Raez et al. using allogeneic CD80 vaccines [31, 32] support this assumption.
A concern with any cell-based vaccine, including the MHC II vaccines described here, is the potential for autoimmunity due to tumor cell-expressed antigens that are shared with non-malignant cells. Autoimmunity has not been observed in the mouse models used to test the MHC II vaccine concept [4, 29] , and there was no response to nonmalignant breast cells in a MHC II vaccine mammary carcinoma system [44] or against normal lung Wbroblast cells as reported here. Collectively, these observations suggest that autoimmunity against normal lung tissue is unlikely to occur. Therefore, the MHC II lung cancer vaccines are active despite the presence of tumor-induced immune suppression, and may be useful immunotherapeutic reagents for NSCLC patients.
